NASDAQ:PSNL

Personalis Stock Forecast, Price & News

$21.52
-0.46 (-2.09 %)
(As of 07/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$20.92
$22.02
50-Day Range
$19.91
$27.75
52-Week Range
$16.01
$53.46
Volume23,174 shs
Average Volume835,125 shs
Market Capitalization$944.90 million
P/E RatioN/A
Dividend YieldN/A
Beta1.51
30 days | 90 days | 365 days | Advanced Chart
Receive PSNL News and Ratings via Email

Sign-up to receive the latest news and ratings for Personalis and its competitors with MarketBeat's FREE daily newsletter.


Personalis logo

About Personalis

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has partnership with Berry Genomics; Natera, Inc.; and MapKure, LLC. Personalis, Inc. was founded in 2011 and is headquartered in Menlo Park, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.58 out of 5 stars

Medical Sector

485th out of 2,214 stocks

Medical Laboratories Industry

10th out of 41 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Personalis (NASDAQ:PSNL) Frequently Asked Questions

Is Personalis a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Personalis stock.
View analyst ratings for Personalis
or view top-rated stocks.

What stocks does MarketBeat like better than Personalis?

Wall Street analysts have given Personalis a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Personalis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Personalis' next earnings date?

Personalis is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Personalis
.

How can I listen to Personalis' earnings call?

Personalis will be holding an earnings conference call on Wednesday, August 4th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Personalis' earnings last quarter?

Personalis, Inc. (NASDAQ:PSNL) posted its quarterly earnings results on Wednesday, May, 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.08. The firm earned $20.88 million during the quarter, compared to analyst estimates of $20.40 million. Personalis had a negative trailing twelve-month return on equity of 21.21% and a negative net margin of 55.43%.
View Personalis' earnings history
.

How has Personalis' stock been impacted by COVID-19 (Coronavirus)?

Personalis' stock was trading at $6.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PSNL stock has increased by 257.5% and is now trading at $21.52.
View which stocks have been most impacted by COVID-19
.

What guidance has Personalis issued on next quarter's earnings?

Personalis issued an update on its second quarter 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $21.30 million-$21.30 million, compared to the consensus revenue estimate of $21.23 million.

What price target have analysts set for PSNL?

8 equities research analysts have issued 12-month price objectives for Personalis' shares. Their forecasts range from $28.00 to $50.00. On average, they expect Personalis' stock price to reach $36.88 in the next year. This suggests a possible upside of 71.4% from the stock's current price.
View analysts' price targets for Personalis
or view top-rated stocks among Wall Street analysts.

Who are Personalis' key executives?

Personalis' management team includes the following people:
  • Mr. John Stephen West, Co-Founder, CEO, Pres & Director (Age 64, Pay $1.03M)
  • Mr. Aaron L. Tachibana, Chief Financial Officer (Age 60, Pay $603.5k)
  • Dr. Richard Chen M.S., M.D., MS, Chief Scientific Officer (Age 50, Pay $638.5k)
  • Prof. Russ B. Altman, Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Euan A. Ashley M.D., Ph.D., FRCP, DPHIL, Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Atul Butte, Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Michael Snyder, Co-Founder and Member of Clinical & Scientific Advisory Board
  • Ms. Carol J. Tillis, VP of Fin. & Admin.
  • Mr. Stephen M. Moore J.D., Gen. Counsel
  • Mr. Michael J. Fitzpatrick, VP of Worldwide Sales

What is John West's approval rating as Personalis' CEO?

17 employees have rated Personalis CEO John West on Glassdoor.com. John West has an approval rating of 75% among Personalis' employees.

Who are some of Personalis' key competitors?

What other stocks do shareholders of Personalis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Enphase Energy (ENPH), Pfizer (PFE), Dynavax Technologies (DVAX), QUALCOMM (QCOM), Advanced Micro Devices (AMD), NIO (NIO), NVIDIA (NVDA), Viking Therapeutics (VKTX), AbbVie (ABBV) and (APHA).

When did Personalis IPO?

(PSNL) raised $100 million in an initial public offering on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is Personalis' stock symbol?

Personalis trades on the NASDAQ under the ticker symbol "PSNL."

How do I buy shares of Personalis?

Shares of PSNL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Personalis' stock price today?

One share of PSNL stock can currently be purchased for approximately $21.52.

How much money does Personalis make?

Personalis has a market capitalization of $944.90 million and generates $78.65 million in revenue each year. The company earns $-41,280,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.

How many employees does Personalis have?

Personalis employs 234 workers across the globe.

What is Personalis' official website?

The official website for Personalis is www.personalis.com.

Where are Personalis' headquarters?

Personalis is headquartered at 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025.

How can I contact Personalis?

Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company can be reached via phone at 650-752-1300 or via email at [email protected]


This page was last updated on 7/26/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.